China
· Delayed Price · Currency is CNY RemeGen Statistics
Total Valuation
RemeGen has a market cap or net worth of CNY 22.43 billion. The enterprise value is 24.42 billion.
| Market Cap | 22.43B |
| Enterprise Value | 24.42B |
Important Dates
The last earnings date was Monday, April 28, 2025.
| Earnings Date | Apr 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 355.03M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.51% |
| Shares Change (QoQ) | +3.03% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 310.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.73 |
| PB Ratio | 12.66 |
| P/TBV Ratio | 13.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -17.78 |
| EV / Sales | 12.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -22.44 |
Financial Position
The company has a current ratio of 0.92, with a Debt / Equity ratio of 1.54.
| Current Ratio | 0.92 |
| Quick Ratio | 0.56 |
| Debt / Equity | 1.54 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.51 |
| Interest Coverage | -16.30 |
Financial Efficiency
Return on equity (ROE) is -56.64% and return on invested capital (ROIC) is -17.74%.
| Return on Equity (ROE) | -56.64% |
| Return on Assets (ROA) | -15.27% |
| Return on Invested Capital (ROIC) | -17.74% |
| Return on Capital Employed (ROCE) | -44.47% |
| Revenue Per Employee | 637,678 |
| Profits Per Employee | -458,014 |
| Employee Count | 2,999 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 0.52 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.79% in the last 52 weeks. The beta is 0.37, so RemeGen's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | -14.79% |
| 50-Day Moving Average | 41.18 |
| 200-Day Moving Average | 32.56 |
| Relative Strength Index (RSI) | 54.07 |
| Average Volume (20 Days) | 6,320,296 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RemeGen had revenue of CNY 1.91 billion and -1.37 billion in losses. Loss per share was -2.54.
| Revenue | 1.91B |
| Gross Profit | 1.55B |
| Operating Income | -1.32B |
| Pretax Income | -1.37B |
| Net Income | -1.37B |
| EBITDA | -1.07B |
| EBIT | -1.32B |
| Loss Per Share | -2.54 |
Balance Sheet
The company has 721.72 million in cash and 2.73 billion in debt, giving a net cash position of -2.01 billion.
| Cash & Cash Equivalents | 721.72M |
| Total Debt | 2.73B |
| Net Cash | -2.01B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.77B |
| Book Value Per Share | 3.21 |
| Working Capital | -184.17M |
Cash Flow
In the last 12 months, operating cash flow was -876.33 million and capital expenditures -211.79 million, giving a free cash flow of -1.09 billion.
| Operating Cash Flow | -876.33M |
| Capital Expenditures | -211.79M |
| Free Cash Flow | -1.09B |
| FCF Per Share | n/a |
Margins
Gross margin is 81.16%, with operating and profit margins of -68.89% and -71.83%.
| Gross Margin | 81.16% |
| Operating Margin | -68.89% |
| Pretax Margin | -71.83% |
| Profit Margin | -71.83% |
| EBITDA Margin | -56.09% |
| EBIT Margin | -68.89% |
| FCF Margin | n/a |
Dividends & Yields
RemeGen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.51% |
| Shareholder Yield | -0.51% |
| Earnings Yield | -6.12% |
| FCF Yield | -4.85% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RemeGen has an Altman Z-Score of 0.96. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.96 |
| Piotroski F-Score | n/a |